School of Medicine, Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey.
School of Medicine, Department of Internal Medicine, Division of Rheumatology, Uludag University, Bursa, Turkey.
Clin Rheumatol. 2022 Jan;41(1):85-94. doi: 10.1007/s10067-021-05893-3. Epub 2021 Sep 3.
To understand change in work productivity, activity impairment, quality of life (QoL), and disease activity in patients with psoriatic arthritis (PsA) receiving anti-tumor necrosis factor (anti-TNF) treatment.
One hundred twenty patients with PsA receiving anti-TNF therapy were recruited to this noninterventional, observational study. Work disability was assessed via the Work Productivity and Activity Impairment (WPAI) questionnaire and disease activity was calculated via the 28-joint Disease Activity Score using C-reactive protein (DAS28-CRP) and Disease Activity Index for Psoriatic Arthritis with 28 joints (DAPSA28) score. Patient-reported outcomes (PROs), from visual analog scores and Health Assessment Questionnaire-Disability Index scores, were evaluated to understand the clinical effectiveness at baseline and every 3 months until the month-9 final visit. The American College of Rheumatology (ACR)20/50/70 response criteria were assessed at month 9.
A total of 120 patients (females, n = 73) were enrolled in the study. Mean (SD) age and disease duration were 41.6 ± 11.1 years and 6.9 ± 6.5 years, respectively. The most commonly used TNFα inhibitor was adalimumab (42.4%), followed by etanercept (25.8%). All WPAI questionnaire parameters were reduced at the follow-up visits compared with baseline (p < 0.001 for all). PROs and disease activity indicators (DAS28-CRP and DAPSA28) significantly improved during the course of anti-TNF treatments (p < 0.001 for all). Additionally, ACR20/50/70 responses were determined as 86.8%, 63.7%, and 41.8% of patients at the month-9 visit.
The real-world data in PsA patients receiving anti-TNF treatment showed improvement in WPAI, QoL, and disease activity over 9 months of treatment.
NCT02028169 Key Points • Psoriatic arthritis (PsA), with debilitating effects on quality of life, occurs mostly in young adults and has negative impacts on employment status and work productivity. • Early PsA diagnosis and treat-to-target treatment strategies aim to reduce pain and joint damage, as well as improve work productivity. • Real-world data on the impact of treatment with anti-tumor necrosis factor (anti-TNF) agents on work productivity in PsA in the literature is scarce. • Our study of real-world data in patients with PsA receiving anti-TNF treatment showed improvement in work productivity, as well as in clinical and patient-reported outcomes.
了解接受抗肿瘤坏死因子（anti-TNF）治疗的银屑病关节炎（PsA）患者的工作生产力、活动障碍、生活质量（QoL）和疾病活动的变化。
本非干预性、观察性研究共招募了 120 名接受抗 TNF 治疗的 PsA 患者。通过工作生产力和活动障碍（WPAI）问卷评估工作障碍，通过 28 关节疾病活动评分（DAS28）使用 C 反应蛋白（DAS28-CRP）和银屑病关节炎 28 关节疾病活动指数（DAPSA28）计算疾病活动。通过视觉模拟评分和健康评估问卷残疾指数评分评估患者报告的结果（PROs），以了解基线和每 3 个月直至第 9 个月最后一次就诊时的临床疗效。在第 9 个月评估美国风湿病学会（ACR）20/50/70 反应标准。
共有 120 名患者（女性，n=73）入组研究。平均（SD）年龄和疾病持续时间分别为 41.6±11.1 岁和 6.9±6.5 年。最常用的 TNFα 抑制剂是阿达木单抗（42.4%），其次是依那西普（25.8%）。所有 WPAI 问卷参数在随访时均较基线降低（均 p<0.001）。在抗 TNF 治疗过程中，PROs 和疾病活动指标（DAS28-CRP 和 DAPSA28）均显著改善（均 p<0.001）。此外，在第 9 个月就诊时，86.8%、63.7%和 41.8%的患者达到了 ACR20/50/70 反应。
接受抗 TNF 治疗的 PsA 患者的真实世界数据显示，在 9 个月的治疗过程中，WPAI、QoL 和疾病活动均有改善。
